Skip to content

Study · Non-randomized trial · 2018

4 results

A Phase II trial of 8 weeks of degarelix for prostate volume reduction: Efficacy and hormonal recovery.

Korzeniowski MA, Crook JM, Bowes D, Gaztañaga M, Ots A, Jazwal J, Rose J, Tétreault-Laflamme A, Pilote L, Halperin R, Kim D, Petrik D, Araujo C, Bachand F

Brachytherapy2 Feb 2018Cited by 3 (Europe PMC)

PMID29398594 (opens in a new tab)DOI10.1016/j.brachy.2017.12.005 (opens in a new tab)PepBankPUB-29398594
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients awaiting prostate brachytherapy, median prostate volume fell from 65.0 to 48.2 cc after degarelix, a 26.2% median decrease.

    In plain wordsIn patients awaiting prostate brachytherapy, median prostate volume decreased by 26.2% after degarelix.

    Peptide
    Degarelix
    Outcome
    DecreaseProstate volume
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 8 weeksAs given in this study (human).

    Measurements

    Baseline volume
    65 cc
    IQR 55.2-80.0
    Volume at 8 weeks
    48.2 cc
    IQR 41.2-59.3
    Median decrease
    26.2%
    IQR 21-31

    Source sentences

    Summary
    The median prostate volume was reduced from 65.0 cc (interquartile range [IQR]: 55.2-80.0 cc) to 48.2 cc at 8 weeks (IQR: 41.2-59.3 cc), representing a median decrease of 26.2% (IQR: 21-31%).
    3 context sentences
    Summary · context
    Fifty patients were accrued to an open-label Phase II clinical trial (www.clinicaltrials.gov ID NCT01446991).
    Summary · context
    Baseline prostate transrectal ultrasound (TRUS) was performed on all patients followed by degarelix administration and a repeat TRUS at Week 8.
    Summary · context
    Brachytherapy was performed within 4 weeks of the 8-week TRUS for all patients who achieved suitable downsizing.
  2. 02HumanNon-randomized trialEfficacy outcome

    In prostate cancer patients, testosterone recovered to an age-adjusted normal range a median 34.1 weeks after the final degarelix injection.

    In plain wordsIn prostate cancer patients, testosterone recovered a median 34.1 weeks after the final degarelix injection.

    Peptide
    Degarelix
    Outcome
    Not applicableTestosterone recovery
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 8 weeksAs given in this study (human).

    Measurements

    Time to recovery
    34.1 weeks
    IQR 28.2-44.5; after final injection

    Source sentences

    Summary
    Functional recovery of testosterone within an age-adjusted normal range occurred at a median of 34.1 weeks (IQR: 28.2-44.5 weeks) from the date of the final injection.
    3 context sentences
    Summary · context
    Fifty patients were accrued to an open-label Phase II clinical trial (www.clinicaltrials.gov ID NCT01446991).
    Summary · context
    Baseline prostate transrectal ultrasound (TRUS) was performed on all patients followed by degarelix administration and a repeat TRUS at Week 8.
    Summary · context
    Brachytherapy was performed within 4 weeks of the 8-week TRUS for all patients who achieved suitable downsizing.
  3. 03HumanNon-randomized trialEfficacy outcome

    In prostate cancer patients after degarelix, follicle-stimulating hormone remained abnormally elevated throughout 12 months despite testosterone recovery.

    In plain wordsIn prostate cancer patients after degarelix, follicle-stimulating hormone remained abnormally high throughout 12 months despite testosterone recovery.

    Peptide
    Degarelix
    Outcome
    IncreaseFollicle-stimulating hormone
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Despite this recovery, follicle-stimulating hormone and luteinizing hormone levels remained abnormally elevated throughout 12 months.
    3 context sentences
    Summary · context
    Fifty patients were accrued to an open-label Phase II clinical trial (www.clinicaltrials.gov ID NCT01446991).
    Summary · context
    Baseline prostate transrectal ultrasound (TRUS) was performed on all patients followed by degarelix administration and a repeat TRUS at Week 8.
    Summary · context
    Brachytherapy was performed within 4 weeks of the 8-week TRUS for all patients who achieved suitable downsizing.
  4. 04HumanNon-randomized trialEfficacy outcome

    In prostate cancer patients after degarelix, luteinizing hormone remained abnormally elevated throughout 12 months despite testosterone recovery.

    In plain wordsIn prostate cancer patients after degarelix, luteinizing hormone remained abnormally high throughout 12 months despite testosterone recovery.

    Peptide
    Degarelix
    Outcome
    IncreaseLuteinizing hormone
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Despite this recovery, follicle-stimulating hormone and luteinizing hormone levels remained abnormally elevated throughout 12 months.
    3 context sentences
    Summary · context
    Fifty patients were accrued to an open-label Phase II clinical trial (www.clinicaltrials.gov ID NCT01446991).
    Summary · context
    Baseline prostate transrectal ultrasound (TRUS) was performed on all patients followed by degarelix administration and a repeat TRUS at Week 8.
    Summary · context
    Brachytherapy was performed within 4 weeks of the 8-week TRUS for all patients who achieved suitable downsizing.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT01446991

Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy

British Columbia Cancer Agencyn = 50Apr 2012 to Dec 2017

Prostate Cancer

Trial pageClinicalTrials.govUpdated 27 Jan 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.